Paper Details

  1. Home
  2. Paper Details

Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?

Author: , DePaoliAlex M, DunnFredrick L, HenryRobert R, HigginsLinda S, MantzorosChristos

Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

INT131 besylate, a potent, nonthiazolidinedione, selective peroxisome proliferator-activated receptor γ (PPARγ) modulator, aims to improve glucose metabolism while minimizing the side effects of full PPARγ agonists. This study compared the effectiveness and side effects of INT131 besylate versus 45 mg pioglitazone HCl in individuals with type 2 diabetes.
Paper Details　
Original Abstract of the Article :
INT131 besylate is a potent, nonthiazolidinedione, selective peroxisome proliferator-activated receptor γ (PPARγ) modulator (SPPARM) designed to improve glucose metabolism while minimizing the side effects of full PPARγ agonists. This placebo-controlled study compared the efficacy and side effects o...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2337/dc13-2480

データ提供：米国国立医学図書館（NLM）

Selective PPARγ Modulators for Type 2 Diabetes: A Comparison

Balancing blood sugar levels is like a camel navigating a treacherous sandstorm – it requires careful attention and the right tools. This study explores a new type of drug called a selective PPARγ modulator (SPPARM), specifically INT131 besylate, for treating type 2 diabetes. It compares this drug to pioglitazone, a more traditional PPARγ agonist, to see if it offers better efficacy with fewer side effects. Think of it like comparing two camels carrying different loads – one might be more efficient and have a smoother ride.

The researchers designed a placebo-controlled study to compare INT131 besylate to pioglitazone. They found that INT131 besylate showed promising results in improving glucose metabolism, while potentially having fewer side effects than pioglitazone. Like a camel with a well-balanced pack, INT131 besylate could offer a more comfortable journey for patients with type 2 diabetes.

INT131 Besylate: A Potential New Option for Type 2 Diabetes

INT131 besylate has emerged as a potential new option for treating type 2 diabetes. This selective PPARγ modulator showed promising results in improving glucose metabolism and may offer a more manageable side effect profile compared to traditional PPARγ agonists.

Type 2 Diabetes and Your Health

Managing type 2 diabetes is essential for maintaining good health. If you're diagnosed with this condition, work with your doctor to find the best treatment plan that suits your needs and helps you achieve optimal blood sugar control.

Dr. Camel's Conclusion

This study provides hope for a new generation of diabetes treatments. INT131 besylate, with its potential for improved efficacy and fewer side effects, could offer a more comfortable and effective journey for patients with type 2 diabetes. As always, consult your doctor for personalized advice and to find the right treatment path for you.

Date :
  1. Date Completed 2014-11-24
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

24722496

DOI: Digital Object Identifier

10.2337/dc13-2480

Related Literature

Article Analysis
・Side Effects of pioglitazone
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.